The reason, on the one hand, people do look forward to the emergence of a body fluid sample of the patient will be able to use the results, while cheap and affordable to everybody detection method;
On the other hand, a year ago, the star of Silicon Valley biotech company Theranos nearly 600 billion "blood test" shattered the myth, the US by storm. Including Murdoch, the Walton family, including a number of the world's leading tycoons are "cut chives" so that "blood test" and "fraud" almost painted on the equal sign.
Today, many science workers to friends who still take the trouble to "school" -
"The core of tumor blood test is the genetic testing currently is viable despite blood samples to detect the direction of the tumor-associated DNA, but it will be some distance away from clinical application this stage we must not blindly follow the blind!"
However, a blood test may be a Japanese company did.
Known as "a drop of blood will be able to find a variety of cancers."
On sale early next year, only a few thousand dollars
According to Japanese media recently reported that the Japanese multinational chemical group Toray Industries, Inc. (Toray Industries, hereinafter referred to as Toray) will be able to find a variety of detection methods for cancer using only a drop of blood in the year 2019, the Japanese Ministry of Health, Labor and Welfare manufacturing applications marketing authorization. If approved, the patient is expected to need tens of thousands of yen (10,000 yen or about 636 yuan) to a one-time detection of a variety of cancers.
"Japanese Economic News" reports screenshot
By the news stimulation, June 10, Toray in the US OTC market rose 5.52 percent.
Toray said that this method can be a variety of cancer screening at the same time, the accuracy rate of over 95%, for early detection of pancreatic cancer is difficult to diagnose cancer and other potentially help. It is reported that, in collaboration with Toray Japan National Cancer Center and other institutions of the project had already started in 2014, if the object is selected as priority review, approval may be put on sale in early 2020.
It reported that when human cancer substance in the blood called "small molecule ribonucleic acid (microRNA)" will increase, Toray developed a chip capable of detecting gene analysis of small RNA molecules in human blood. After Toray developed a chip on the market other than the small molecules of ribonucleic acid detection chip 100 times more sensitive.
It reported that small RNA molecules involved in gene activity is a matter of human memory in about 2600 kinds of the substance. After cancer secrete specific small RNA molecules, and proliferation or metastasis. Toray research project, successfully locked five, colorectal cancer breast cancer three kinds of cancer and other key master a variety of small RNA molecules.
In fact, Toray, the company's health care materials are only a small piece of business. Although calculated according to market share, Toray is the world's leading carbon fiber suppliers, but at the end of the fiscal year ended March this year, the life science part of the Toray only 2% of sales, while the fibers and textiles accounted for 41% of Group sales.
In fact, in the United States, with the patient's blood to detect cancer had already achieved, the researchers studied the Kimmel Cancer Center at Johns Hopkins University on the development of a common type of cancer can be screened eight kinds of single blood test last year, which also help locate cancer.
In addition, in the ASCO (American Society of Clinical Oncology) Annual Meeting held recently, there are reports data showed the US GRAIL developed a variety of cancer blood test can also be found in 12 kinds of fatal cancer from the blood at an early stage, specific at least 99% (equivalent to not say the possibility of cancer into cancer less than 1%).
This means testing recently identified breakthrough medical devices FDA granted. ASCO report contains results of detection of 2301 subjects, of which 1422 in subjects suffering from different stages of cancer, while 879 subjects has not been diagnosed with cancer at the time of detection.
Remember the billions of dollars in Silicon Valley last year scam you?
In fact, a few years ago, there is a Silicon Valley start-up company claims to achieve a similar technology with Toray "blood test cancer." However, due to the presence of fraud was later discovered, many well-known investor is cut leeks, the company fell into liquidation.
This was very popular in Silicon Valley biotech company called Theranos, the main business is the blood test. Company founder Elizabeth Holmes (Elizabeth Holmes) has said that she invented a breakthrough innovative technology, the acquisition by a fingertip, two drops of blood, that can be done only in specialized laboratories fully to complete detection.
Elizabeth Holmes
Even better, the company is committed to Holmes blood test product development, blood test their invention to facilitate affordable, fair and transparent known. Previously, when patients go to the hospital clinic blood test, will have to spend hundreds of dollars at every turn, but with Theranos minimum product as long as the US dollar (about 20.68 yuan) 2.99.
Then Theranos will undoubtedly become a Silicon Valley star company.
October 2015, the Silicon Valley 101 CEO, investors and members of think tank for "what a start-up companies will change the world" vote. As a result, start-up companies Theranos behind Tesla, in second place. With these so-called "disruptive" technology, Theranos valuations soared, its peak reached 90 billion US dollars (about 57.2 billion yuan).
In 2003, 19-year-old initiative Holmes dropped out of Stanford in sophomore year, holding the parents save for college tuition investment business. "Ten years sword", in 2014, the company prospered, valued at $ 9 billion. At that time Theranos have an "all-star board of directors", as technical adviser and founder of directorships in addition to Holmes, there are former US Secretary of State Henry Kissinger and former US Secretary of Defense, senator, Admiral and other big shot . A large group of former senior government officials in their 80s and 90s to early 30s beauty of a start-up companies the platform, this spectacle shook the United States of biology.
Holmes himself in 2014 by Forbes magazine to be the year-end cover.
Forbes magazine cover
However, in October 2015, "Wall Street Journal" scandal exposed Theranos shaking, then the company is facing from the medical authorities, investors, the US Securities and Exchange Commission (SEC), Medicare and Medicaid Services (CMS), the state Attorney General long, former business partners, patients and other aspects of a series of lawsuits.
It is estimated that in June 2016, Holmes's personal net assets from $ 4.5 billion to almost zero. July 2016, Theranos CMS sanctions, including revocation of its CLIA certificate. September 2018, Theranos officially ceased operations.
In March last year, civil fraud charges against Holmes, the United States Securities and Exchange Commission (SEC) directly to the allegations as a lie, saying Theranos using commercial equipment made by other companies carried out most of the blood test.
At that time, Holmes has neither admitted nor denied the allegations, but she returned most of her Theranos stock, gave up control of the company, paid $ 500,000 in fines, also agreed to ban her at any any penalties listed company senior management positions for up to ten years.
"Blood test cancer" fly it?
It is micro-channel public, "Chinese science" push an article a few days ago, the current methods of cancer diagnosis, genetic testing is on histopathological examination of biopsy specimens and tissue mutation.
Of course, biopsy also has great disadvantages. E.g:
1, drawn often require invasive surgery, will increase the suffering of patients.
2, local tissue removed not necessarily representative of the overall situation of the tumor.
3, a single reaction progress of the disease can not be drawn, it is difficult for patients integrity and sustainability assessment.
As mentioned at the beginning of the article, with blood samples it is feasible to detect the direction of tumor-associated DNA. Chinese science believes that in the near future, perhaps not only "blood test cancer", also "spit test cancer." But not now - similar technology is currently in the country is not yet mature, and no large-scale applications.
Dalian Women's Hospital that good home mobile.0411bh.com